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Abstract 
Photostability of amisulpride, doxepin, haloperidol, risperidone, venlafaxine, and zopiclone in APIs and powdered tablets 
during exposure to UVA irradiation was studied. In order to evaluate the photodegradation process an ultrahigh performance 
liquid chromatography method coupled with tandem mass spectrometry (UHPLC-MS/MS) was developed and validated. It 
was found that the photodegradation of the studied compounds depends on the type of drug and co-existing excipients. Dif-
ferent percentage of photodegradation of the studied drugs was observed, and therefore amisulpride decomposed at 2.63% 
in bulk drug and at 5.74% in pharmaceutical preparation, doxepin: 29% and 72.38%, haloperidol: 3.71% and 26.20%, risp-
eridone: 7.13% and 12.86%, venlafaxine: 38.59% and 4.22%, zopiclone: 18.62% and 31.42% respectively, after 114 days of 
UVA irradiation. In addition, kinetic evaluation of the photodegradation process was performed by determining the order of 
reaction, reaction rate constant k and time t0.1 and t0.5. The photodegradation products of studied drugs were identified, and 
their fragmentation pathways, derived from MS/MS data, were proposed. The photostability testing is an integral part of the 
drug stability assessment to ensure quality, efficacy and safety of the formulated products during manufacturing process, 
storage as well as normal use.
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Introduction
One of numerous factors influencing stability of the drug, 
is light which initiates the process of photochemical con-
version, leading to changes in the chemical structure of the 
exposed compound. The problem of interaction between 
light and pharmaceutical products is important in the drug 
formulation technology during both, technological processes 
and storage as well. Irradiation can lead to the reduction or 
loss of drug activity, as well as formation of toxic products 
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of photodegradation. Therefore, photostability testing is an 
integral part of the assessment of the drug stability, which is 
important at the stage of drug development and its registra-
tion aiming at ensuring its safety and efficacy [1–5].
Active pharmaceutical ingredients (APIs) may be directly 
or indirectly exposed to radiation. Direct photochemical 
reactions occur when API degradation is the result of direct 
light excitation of its molecules. The substance will only 
degrade if it comes in contact with radiation of an appropri-
ate wavelength. In the case of an indirect (sensitized) photo-
reaction there is a transfer of excitation energy to a molecule 
(e.g. API) other than the compound which initially absorbs 
the radiation. The compound that absorbs the radiation, the 
photosensitizer (e.g. excipient, impurity), is initially trans-
formed from its ground state (singlet state) into a relatively 
long-lived excited triplet state. The excited triplet state can 
mediate a photosensitized reaction due to the long lifetime 
and bi-radical nature with unpaired electron spins [6]. There-
fore, both the excipients and the type of preparation could 
influence the photoreactivity of the drug substance.
The purpose of this work was to study the photostabil-
ity of selected drugs in APIs and powdered tablets during 
exposure to UVA irradiation. Furthermore, we studied the 
impact of excipients present in tablets on the photodegrada-
tion process. In order to evaluate the photodegradation pro-
cess we have developed and validated an ultrahigh perfor-
mance liquid chromatography method coupled with tandem 
mass spectrometry (UHPLC-MS/MS) for the determination 
of APIs and their phodegradation products. In addition, the 
kinetic evaluation of the photodegradation process was car-
ried out and photodegradation products have been identi-
fied. The investigations have been performed on the group 
of drugs belonging to the central nervous system agents rep-
resenting different structural groups. The selection of drugs 
was based on their properties, availability and photodegra-
dation process. In the study the following drugs were used: 
amisulpride, doxepin, haloperidol, risperidone, venlafaxine, 
zopiclone which undergo photodegradation process.
Amisulpride (AMI, (RS)-4-amino-N-[(1-ethylpyrrolidin-
2-yl)methyl]-5-ethylsulfonyl-2-methoxy-benzamide) is an 
atypical neuroleptics used in the treatment of schizophre-
nia, dysthymia, and mild-moderate depression. Doxepin 
(DOX, 11-(3-dimethylaminopropylidene)dibenzo[b,e]-
oxepin), belongs to the group of tricyclic antidepressants 
(TCAs), oxepin derivatives. It has an anxiolytic and seda-
tive effect. Haloperidol (HAL, 4-[4-(4-chloro)-4-hydroxy-1-
piperidinyl]-1(4-fluorophenyl)-1-butanone), is a derivative 
of butyrophenone. It has a strong antipsychotic and sedative 
effect. Risperidone (RIS, 3-[2-[4-(6-fluoro-1,2-benzoxazol-
3-yl)piperidin-1-yl]ethyl]-2-methyl-4H,6H,7H,8H,9H-
pyrido[1,2-a]pyrimydin-4-one), is a benzoxazole deriva-
tive. It is a second generation anti-psychotic drug, used 
in the treatment of schizophrenia. Venlafaxine (VEN, 
(RS)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-
cyclohexanol) is a third generation antidepressant drug, it 
belongs to the group of selective serotonin-norepinephrine 
reuptake inhibitors (SNRIs). Zopiclone (ZOP, (RS)-6-(5-
chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]-
pyrazin-5-yl-4-methylpiperazine-1-carboxylate) is a hyp-
notic, ciclopirolone derivative. It has hypnotic, sedative, 
anxiolytic effect.
Photostability of some of the investigated drugs is a 
subject of a few research publications: and so, by UHPLC 
method coupled with mass detection, AMI degradation 
products in methanol solutions were identified under the 
influence of UVA radiation [7]. For the identification of 
photodegradation products of aqueous DOX solutions, TLC 
with densitometric detection was used [8, 9]. Photostabil-
ity of VEN in aqueous solutions was evaluated using LC/
MS method [10], and the effect of UVA on the stability of 
solutions containing ZOP was evaluated by capillary elec-
trophoresis [11].
In the available literature, no data on the photodegra-
dation studies in solid state of the drugs we selected were 
found.
Results and discussion
Method validation
UHPLC-MS/MS used in the photostability study of AMI, 
DOX, HAL, RIS, VEN, and ZOP was validated by evalu-
ation of its specificity, accuracy, precision, linearity range, 
limit of detection, and limit of quantification. The developed 
method provides satisfactory separation of the tested phar-
maceutical substances from their photodegradation products 
as evidenced by the values of resolution factor Rs calculated 
based on equation Rs = 2 (tR2 − tR1)/(W1 + W2) where tR1, 
tR2—retention time for peak 1 and 2, respectively; W1, W2—
peak widths at the base [s] for peak 1 and 2, respectively.
The main peak purity was examined with MS spectra 
using CODA algorithm (Waters Corporation, Milford, MA, 
USA). The investigated MS spectra uniquely contained sig-
nals corresponding to the examined substances and solvent.
Recovery percent of the tested components shown as 
average values for three concentration levels was satisfac-
tory, and ranged between 97.08 and 104.17%. High precision 
determined for three concentration levels was confirmed by 
the RSD values ranging from 0.06 to 2.95%.
Linearity was maintained over a concentration range, 
from 0.306 to 2.040  mg  cm−3 for AMI, from 0.300 to 
2.00 mg cm−3 for DOX, from 0.321 to 1.926 mg cm−3 for 
HAL, from 0.214 to 2.140 mg cm−3 for RIS, from 0.204 to 
1.836 mg cm−3 for VEN, and from 0.315 to 2.100 mg cm−3 
for ZOP. Linear determination coefficient R2 did not specify 
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clearly the linearity of the calibration method [12]. There-
fore, to assess the linearity, Mandel’s test was used. Compar-
ative results of linear and quadratic fit of the studied drugs 
indicate linear fit of calibration curves for HAL and RIS. 
The p-values indicate the significance of the slopes and non-
significance of the intercepts. In other cases, quadratic fit 
was obtained. The results of Mandel’s test (p = 0.685) indi-
cate equal contribution of linear and quadratic fit for ZOP 
calibration, however due to the statistical significance of the 
intercept in the linear model, quadratic model was selected. 
The normality of residuals distribution was confirmed by 
the Shapiro–Wilk test. The results of the Durbin–Watson 
(D–W) test showed no significant autocorrelation of random 
components, except for DOX, RIS, and ZOP. For the above-
mentioned drugs, D–W test did not decide on the presence 
or absence of autocorrelation, therefore Lagrange multiplier 
test was performed. The results of this test indicate no signif-
icant autocorrelation of random components in the selected 
models. Constant variance of random components in the 
proposed fits was checked using Bartlett test. The obtained 
results indicate the presence of constant variance in all cases 
(p-value > 0.05) (Table 1).
Sensitivity of the developed methods was estimated, 
LOD was at 0.087 mg cm−3 for AMI, 0.068 mg cm−3 for 
DOX, 0.077 mg cm−3 for HAL, 0.046 mg cm−3 for RIS, 
0.024 mg cm−3 for VEN, and 0.095 mg cm−3 for ZOP, LOQ 
estimated at 0.264 mg cm−3, 0.205 mg cm−3, 0.233 mg cm−3, 
0.139  mg  cm−3, 0.072  mg  cm−3, and 0.288  mg  cm−3, 
respectively.
Table 1   Linear and quadratic equation of examined substances
* For quadratic equation; P, peak surface area  [mm2]; c, concentration of solution [mg  cm−3]; R2, coefficient of determination; (p), p signifi-
cance; SW, Shapiro–Wilk; DW, Durbin–Watson; LM, Lagrange multiplier test
Substance Linear equation
(p)
Quadratic equation
(p)
R2 Mandel’s test
(p)
AMI P = 13,776,164c + 1,132,199 P = − 1,119,232c2 + 116,327,583c + 76,297 0.9991* 33.27
(0.000)
(0.000) (0.000) (0.000) (0.000) (0.743)
DOX P = 11,480,140c + 913,098 P = − 1,281,012c2 + 1,434,3095c – 248,501 0.9991* 61.49
(0.000)
(0.000) (0.003) (0.000) (0.000) (0.201)
HAL P = 7,927,836c − 165,091 P = − 307,348c2 + 8,585,562c – 423,473 0.9982 3.863
(0.075)
(0.000) (0.161) (0.075) (0.000) (0.026)
RIS P = 8,378,351c – 52,715 P = 1,31,629c2 + 8,063,578c + 83,937 0.9996 4.206
(0.061)
(0.000) (0.534) (0.062) (0.000) (0.332)
VEN P = 3,598,226c + 126,161 P = − 94,150c2 + 3790292c + 54,235 0.9998* 9.558
(0.010)
(0.000) (0.000) (0.010) (0.000) (0.090)
ZOP P = 7,816,537c + 519,263 P = − 46,535c2 + 7,925,741c + 472,739 0.9990* 0.172
(0.685)
(0.000) (0.000) (0.685) (0.000) (0.005)
Substance SW test
(p)
DW test LM test
(p)
Bartlett test
(p)
AMI 0.921*
(0.181)
1.735* – 0.042
(0.837)*
DOX 0.974*
(0.903)
1.434* 1.087
(0.297)*
3.027
(0.082)*
HAL 0.910
(0.156)
1.415 – 0.003
(0.955)
RIS 0.929
(0.241)
1.194 2.295
(1.130)
0.462
(0.497)
VEN 0.946*
(0.501)*
1.848* – 0.181*
(0.673)*
ZOP 0.941
(0.275)*
1.370* 1.480
(0.224)*
1.189
(0.275)*
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Photostability study of the analyzed substances 
in bulk drug and in powdered tablets
Studies of the effect of UVA on AMI, DOX, HAL, RIS, 
VEN, and ZOP in bulk drug and in powdered tablets demon-
strated, that they undergo photodegradation, which proceeds 
at different speeds, depending on the type of API and excipi-
ents in drug dosage form. In the registered chromatograms, 
differences in the number of additional peaks as well as in 
retention times (tR) were observed. Different decomposition 
rate of a given substance in bulk drug and in a pharmaceuti-
cal preparation was reported. In most cases, these differences 
also include the number of resulting products occurring due 
to the photodegradation process. However, no changes were 
observed during irradiation of dark control samples.
As a result of AMI decomposition in both, bulk drug and 
pharmaceutical preparation, three products were formed: 
AP-1, AP-2, and AP-3, in the case of DOX eleven products 
Fig. 1  Chromatograms of AMI, 
DOX, and HAL recorded after 
114 days of irradiation with 
UVA. a Irradiation of bulk 
drug, b irradiation of powdered 
tablets
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(DP-1–DP-11) were identified in both irradiated samples. 
Under the influence of UVA six products were formed in the 
preparation containing HAL: HP-1–HP-6, five in the irradi-
ated substance: HP-1, HP-2, HP-3, HP-5, and HP-6 (Fig. 1).
Both irradiated RIS samples decomposed into three prod-
ucts: RP-1, RP-2, and RP-3. VEN in bulk drug decomposed 
into six products: VP-1–VP-6, whereas in the pharmaceuti-
cal preparation only into four VP-1, VP-3, VP-5, and VP-6. 
Six products of photodegradation were formed in the case of 
ZOP, both in bulk drug and in the pharmaceutical prepara-
tion: ZP-1–ZP-6 (Fig. 2).
Different percentage of photodegradation of the studied 
drugs was observed, and therefore AMI decomposed at 
2.63% in bulk drug and at 5.74% in pharmaceutical prepara-
tion, DOX: 29% and 72.38%, HAL: 3.71% and 26.20%, RIS: 
7.13% and 12.86%, VEN: 38.59% and 4.22%, ZOP: 18.62% 
and 31.42% respectively, after 114 days of UVA irradiation 
with estimated standard deviation calculated as uncertainty 
Fig. 2  Chromatograms of RIS, 
VEN, and ZOP recorded after 
114 days of irradiation with 
UVA. a Irradiation of bulk 
drug, b irradiation of powdered 
tablets
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from periods (12, 26, 44, 56, 79, 91, and 114 days) on the 
assumption of first order kinetics (Fig. 3). In majority of 
the studied drugs, higher decomposition occurs in powdered 
tablets than in bulk drug, except for VEN, for which the 
situation is reversed: in bulk drug, photodegradation occurs 
faster than in the pharmaceutical preparation.
Differences in photodegradation between the API and 
the pharmaceutical preparation can be justified by the 
presence of excipients in the form of drug. The effect of 
UV radiation on these substances is diverse: they can be 
inhibitors of photochemical reactions, be susceptible to 
attack of free radicals and inhibit the decomposition of 
the active substance, they can undergo photodegradation, 
they can also be a source of peroxides and also participate 
in free radical reactions [13, 14].
Increased decomposition in the tablets as compared to 
a bulk drug may be caused by the presence of excipients, 
particularly  TiO2 exhibiting photocatalytic properties [15] 
associated with absorption of radiation. As a result, the 
energy of photons absorbed by  TiO2 can be converted into 
chemical energy leading to the formation of hydroxyl radi-
cals (e.g. from water vapor). In the case of RIS and ZOP, 
the irradiated tablet mass contained  TiO2.
Among the tested drugs AMI, DOX, VEN, and HAL 
preparations do not contain  TiO2 in powdered mass of the 
tablet. In terms of AMI tablets, photodegradation occurs to 
a lesser degree. As mentioned above, VEN in bulk drug 
decomposes to a greater extent as compared to pharmaceu-
tical preparation. Taking into account slight differences in 
the composition of excipients, which relate to the presence 
of the Eudragit RS 100 copolymer, one can assume that 
this substance may weaken the direct effect of UV radia-
tion. In the checked literature, publications describing the 
research showing the protective action of Eudragit against 
UV–VIS radiation on pantoprazole [16, 17], ranitidine [18], 
clotrimazole [19], and microorganisms Spodoptera fru-
giperda multiple nucleopolyhedrovirus [20, 21] were found.
In addition, among the tested pharmaceutical preparations 
DOX, RIS, and ZOP contained in their composition talc, 
which has nucleating properties and can increase the light 
transmission of the powdered tablet mass, similar to nucle-
ated polymers [22, 23].
The observed differences in photodegradation processes 
occurring in the studied drugs may also be associated with 
diverse chemical structures of individual substances.
Kinetics study
Changes in the concentration of the studied drugs occurring 
during UVA irradiation were determined in accordance with 
first-order reaction kinetics (Fig. 4) calculating the reaction 
rate constant k, degradation half-times t0.5 and t0.1, after 
which 50% and 10% of initial substances undergo degrada-
tion, respectively.
The calculated values of reaction rate constants of pho-
todegradation in the case of the most studied drugs have 
different values and vary from the lowest for AMI and HAL 
to the highest for DOX in bulk drug, and in pharmaceuti-
cal preparations from AMI and VEN to DOX, respectively 
(Table 2).
Identification of degradation products
The structures of photodegradation products of AMI, DOX, 
HAL, RIS, VEN, and ZOP were proposed on a basis of 
UHPLC/MS analysis supported with fragmentation patterns 
obtained from MS/MS experiments. The proposed degradation 
products are shown in Figs. 1, 2 with parameters in Table 3.
In case of AMI it seems that the photodegradation 
mainly involved dealkylation of pyrrolidine moiety (AP-
1) or hydroxylation of ethyl substituent of nitrogen atom 
of pyrrolidine moiety (AP-2). Additionally one product of 
dealkylation of nitrogen atom of amide moiety with subse-
quent rearrangement was observed (AP-3).
In case of DOX the CAD experiments suggest that the 
photodegradation process mainly involved hydroxylation of 
propylidenyl chain (DP-1–DP-4, DP-6) and/or hydratation 
of double bond between propylidene chain and oxepine ring 
(DP-1 and DP-2). In case of products DP-1, DP-2, and DP-4 
it seems that the photodegradation involved also oxidation of 
oxepine ring in close vicinity to oxygen atom. It seems that 
only in case of DP-5 oxidation took place in one of the phenyl 
rings. Further oxidation of DOX led to oxepine ring opening 
(DP-7–DP-9), demethylation of amine moiety (DP-7) and deg-
radation of propylidene chain (DP-8–DP-11). Product DP-10 
seems to be intramolecular condensation product of DP-8.
Fig. 3  Comparison of the decomposition percentage of the studied 
drugs (± SD) in a bulk drug and in pharmaceutical preparation
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In case of HAL the photodegradation process seems to 
involve dealkylation of nitrogen atom of piperidine ring 
(HP-1) with subsequent dehydrogenation (HP-2), opening of 
piperidine ring (HP-3), its hydroxylation (HP-4), or hydroxy-
lation of phenyl ring of 4-(4-chlorophenyl)-piperidin-4-ol 
moiety (HP-5 and HP-6).
Fig. 4  The dependence of log c = f(t) for: a amitriptiline, b doxepine, c haloperidol, d risperidon, e venlafaxine, and f zopiclon photodegradation 
in the dark control samples (dot line), bulk drug (dash line) and tablets (solid line)
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The photodegradation of RIS seems to involve dealkyla-
tion of nitrogen atom of piperidine ring (RP-1), hydroxyla-
tion of phenyl ring of benzo[d]isoxazole moiety (RP-2), or 
substitution of fluorine at the benzo[d]isoxazole moiety with 
hydroxyl group (RP-3). Additionally for RP-3 opening of the 
isoxazole ring was observed.
The photodegradation of VEN seems to involve oxida-
tion of methylene group in close vicinity to the nitrogen 
atom (all major products, VP-1–VP-6) and C–C bond 
breaking between cyclohexyl moiety and ethylene chain 
(VP-1–VP-5). Additionally for product VP-2 further oxida-
tion of ethylene chain was observed, and for products VP-1 
and VP-4 demethylation of oxygen (VP-1) or nitrogen (VP-
4) atom took place.
In case of ZOP the photodegradation process seems to 
involve degradation of pyrrolone ring (ZP-2, ZP-3, ZP-6), 
hydroxylation of piperidine moiety (ZP-1 and ZP-4), loss of 
(4-methylpiperazinyl)carboxyl moiety or its fragment (ZP-
2, ZP-3, ZP-5, and ZP-6). For ZP-4 loss of chloropyridinyl 
moiety was observed.
Conclusions
The developed UHPLC method meets the criteria of valida-
tion and may be used for the determination of AMI, DOX, 
HAL, RIS, VEN, and ZOP in the presence of their photo-
degradation products. Photodegradation of the studied sub-
stances follows first-order kinetics. It was found, that most of 
the investigated drugs decompose much faster in powdered 
tablets than in bulk drug substance, except for VEN, which 
decomposes tenfold faster in bulk drug than in the form of 
tablets. Calculated values of the kinetic parameters (k, t0.1, 
and t0.5) show that the quickest decomposition is observed 
for DOX in both, substance as well as in pharmaceutical 
preparation, and the slowest decomposition is observed for 
AMI and HAL substances and powdered tablets containing 
AMI and VEN.
Using mass spectrometry, photodegradation products 
were identified followed by the establishment of their 
structure.
Experimental
Amisulpride (99.9%), doxepin hydrochloride (99.5%), halo-
peridol (99.9%), risperidone (99.7%), venlafaxine hydro-
chloride (99.8%), zopiclone (99.4%) (LGC Promochem 
[Ltd.], Poland). Methanol and acetonitrile of analytical 
grade (Chempur, Piekary Śląskie, Poland). Acetonitrile of 
LC–MS grade and formic acid (98%) (Sigma-Aldrich), water 
for HPLC from HLP 5 generator (HYDROLAB Poland).
Pharmaceutical preparations
Solian—tablets containing 200 mg of amisulpride (Sanofi 
Aventis, Paris, France). Excipients: sodium starch glycolate 
(type A), lactose monohydrate, microcrystalline cellulose, 
hypromellose, magnesium stearate.
Doxepin—hard capsules containing 10 mg of doxepin 
hydrochloride (Pliva Cracow, Poland). Excipients: lactose 
monohydrate, maize starch, gelatinised starch, talc, magne-
sium stearate, Hard capsule shell: gelatin, titanium dioxide, 
erythrosine, brilliant blue.
Haloperidol WZF—tablets containing 5 mg of haloperi-
dol (Warsaw Pharmaceutical Works Polfa, Warsaw, Poland). 
Excipients: lactose monohydrate, microcrystalline cellulose, 
colloidal hydrated silica, croscarmellose sodium, magne-
sium stearate.
Risperdal—coated tablets containing 4 mg of risperidone 
(Janssen-Cilag, Val-de-Reuil, France). Tablet core: lactose, 
maize starch, microcrystalline cellulose, hypromellose, mag-
nesium stearate, colloidal anhydrous silica, sodium lauryl 
sulfate. Tablet coating: propylene glycol, titanium dioxide, 
talc, indigo carmine, quinoline yellow.
Venlectine—prolonged-release hard capsules containing 
37.5 mg of venlafaxine hydrochloride (ICN Polfa Rzeszów, 
Rzeszów, Poland). Tablet core: hypromellose, eudragit RS 
100, sodium lauryl sulfate, magnesium stearate. Tablet 
coating: eudragit RS 100. Capsule shell: titanium dioxide, 
gelatin.
Senzop—coated tablets containing 7.5 mg of zopiclone 
(Jelfa, Jelenia Gora, Poland). Tablet core: calcium hydro-
gen phosphate dihydrate, lactose monohydrate, maize starch, 
sodium starch glycolate (type A), magnesium stearate. Tab-
let coating: hypromellose, propylene glycol, talc, titanium 
dioxide.
Table 2  Kinetic parameters of UVA photodegradation
Substance 
name
Drug 
form
k/day−1 t0.5/days t0.1/days Correlation 
coefficient r
AMI Bulk drug 2.303⋅10–4 3009.12 457.23 − 0.9566
Tablets 4.606⋅10–4 1504.56 228.61 − 0.9625
DOX Bulk drug 3.454⋅10–3 200.61 30.48 − 0.9910
Tablets 1.080⋅10–2 64.05 9.73 − 0.9602
HAL Bulk drug 2.303⋅10–4 3009.12 457.23 − 0.8674
Tablets 2.764⋅10–3 250.76 38.10 − 0.9962
RIS Bulk drug 6.909⋅10–4 1003.04 152.41 − 0.9811
Tablets 1.151⋅10–3 601.82 91.44 − 0.9666
VEN Bulk drug 5.067⋅10–3 136.78 20.78 − 0.9923
Tablets 4.606⋅10–4 1504.56 228.61 − 0.9755
ZOP Bulk drug 1.151⋅10–3 601.82 91.44 − 0.9809
Tablets 2.303⋅10–3 300.91 45.72 − 0.9652
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Standard solutions
Calibration standard solutions of examined substances were 
prepared in methanol. Standard solutions were prepared in 
concentration ranges: AMI from 0.204 to 2.040 mg cm−3; 
DOX from 0.200 to 2.000 mg cm−3, HAL from 0.214 to 
2.140 mg cm−3, RIS from 0.214, to 2.140 mg cm−3, VEN from 
0.204 to 2.040 mg cm−3, ZOP from 0.210, to 2.100 mg cm−3.
Irradiation conditions and preparation of samples
On Petri dishes with a diameter of 5.7 cm, 30.0 mg of 
the examined substances and powdered tablet formulation 
containing 30.0 mg of active substance, was weighed. For 
each sample, dark control sample was prepared, which 
was protected from radiation by four layers of aluminum 
foil.
Table 3  Proposed products 
of photodegradation of 
amisulpride, dexepine, 
haloperidol, risperidone, 
venlafaxine, and zopiclone
Product id RT [M+H]+ Fragmentation ions
AP-1 2.42 342.2 84.1, 101.1, 127.1, 214.1, 242.1
AMI 2.61 370.2 84.1, 112.1, 129.1, 155.1, 214.1, 242.1
AP-2 2.87 386.2 84.1, 110.1, 128.1, 145.1, 171.1, 214.1, 242.1
AP-3 3.60 287.0 242.0
DP-1 3.50 314.2 58.1, 72.1, 102.1, 107.0, 205.1, 223.1, 233.1, 251.1, 296.2
DP-2 3.55 328.2 58.1, 219.1, 264.1, 292.1, 310.1
DP-3 3.70 312.2 58.1, 88.1, 98.1, 195.1, 249.1, 294.1
DP-4 3.75 326.1 58.1, 88.1, 98.1, 209.1, 247.1, 262.1, 281.1, 290.1, 308.1
DP-5 4.01 296.2 58.1, 107.0, 223.1, 251.1
DP-6 4.13 296.2 58.1, 88.1, 107.0, 233.1, 278.2
DOX 4.39 280.2 58.1, 72.1, 84.1, 107.0, 207.1, 221.1, 235.1
DP-7 5.21 256.1 119.0, 162.1, 193.1, 211.1
DP-8 5.34 229.1 135.0, 193.1, 211.1
DP-9 5.47 243.1 149.1, 225.1
DP-10 6.39 211.1 183.1, 193.1
DP-11 6.82 211.1 77.0, 105.0, 183.1
HP-1 2.89 212.1 194.1
HP-2 3.56 190.0 –
HP-3 4.20 376.2 123.0, 165.1, 358.1
HP-4 4.30 392.1 123.0, 165.1, 192.1, 210.1, 356.1, 374.1
HAL 4.50 376.2 123.0, 165.1, 358.1
HP-5 4.80 392.1 123.0, 165.1, 374.1
HP-6 5.06 392.1 123.0, 165.1, 374.1
RP-1 3.14 221.1 84.1, 95.0
RIS 3.47 411.2 191.1
RP-2 3.81 427.2 191.1, 235.1
RP-3 4.07 411.2 191.1
VP-1 1.37 180.1 107.0
VP-2 1.56 210.1 121.1, 137.1
VP-3 2.03 196.1 121.1, 148.1, 162.1, 178.1
VP-4 2.12 180.1 121.1, 148.1, 162.1
VP-5 2.20 194.1 121.1
VP-6 2.37 292.2 121.1, 166.1, 201.1, 229.1, 274.2
VEN 3.66 278.2 121.1, 147.1, 215.1, 260.2
ZOP 3.01 389.1 99.1, 112.0, 217.0, 245.0
ZP-1 3.29 405.1 99.1, 112.0, 217.0, 245.0
ZP-2 3.56 279.0 81.0, 107.0, 112.0, 155.0, 235.0
ZP-3 3.76 200.0 112.0, 155.0
ZP-4 3.81 278.1 81.0, 107.0, 147.1, 172.1, 260.1
ZP-5 4.83 247.0 81.0, 107.0, 112.0, 141.0, 219.0
ZP-6 5.35 235.0 81,0, 107.0, 112.0, 155.0
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The samples were inserted into the climatic chamber KBF-
ICH 240 APT.line (Binder GmbH, Tuttlingen, Germany) and 
exposed to UVA irradiation. Irradiation was carried out under 
the following conditions: range of radiation 320–400 nm 
with maximum emission at λ = 365 nm at 20 °C and relative 
humidity of 60%. The samples were placed at a distance of 
13 cm from the radiation source. Dose of emitted radiation 
was determined using VLX-3 radiometer (Vilber Lourmat) 
with CX-365 sensor and each time was 5.09⋅10–3 J cm min−1. 
Every few days, the samples were thoroughly mixed. The 
exposure time of the samples was chosen experimentally. 
Irradiation was stopped when the degradation of the more 
labile samples reached about 30%. After irradiation for a par-
ticular number of days, substances were dissolved in metha-
nol and the powdered tablet formulation was extracted into 
methanol and centrifuged to obtain solutions at concentra-
tions of approximately 1.00 mg cm−3. The obtained solutions 
were then analyzed by UHPLC-MS/MS method.
UHPLC‑MS/MS analysis
The UHPLC-MS/MS system consisted of a Waters 
 ACQUITY®  UPLC® (Waters Corporation, Milford, 
MA, USA) coupled to a Waters TQD mass spectrometer 
(electrospray ionization mode ESI-tandem quadrupole). 
Chromatographic separations were carried out using 
the Acquity UPLC BEH (bridged ethyl hybrid)  C18 col-
umn; 2.1 × 100 mm, and 1.7 µm particle size, equipped 
with Acquity UPLC BEH C18 VanGuard pre-column; 
2.1 × 5 mm, and 1.7 µm particle size. The column was main-
tained at 40 °C, and eluted under gradient conditions using 
from 95 to 0% of eluent A over 10 min, at a flow rate of 0.3 
 cm3 min−1. Eluent A: 0.1% v/v formic acid in water; eluent 
B: 0.1% v/v formic acid in acetonitrile.
Chromatograms were recorded using Waters eλ PDA 
detector. Compound concentration (%i) after photodegra-
dation was calculated by using the internal normalization 
method according to formula: %i = Ai/∑A⋅100%, where Ai 
is peak area of the constituent being determined, and ∑A 
is the sum of peak areas for all constituents present in the 
chromatogram. Spectra were analyzed in 200–700 nm range 
with 1.2 nm resolution and sampling rate 20 points/s.
MS detection settings of Waters TQD mass spectrometer 
were as follows: source temperature 150 °C, desolvation 
temperature 350 °C, desolvation gas flow rate 600  dm3 h−1, 
cone gas flow 100  dm3 h−1, capillary potential 3.00 kV, cone 
potential 20 V. Nitrogen was used for both nebulizing and 
drying gas. The data were obtained in a scan mode ranging 
from 50 to 1000 m/z in time 0.5 s intervals; 8 scans were 
summed up to get the final spectrum.
Collision activated dissociations (CAD) analyses were 
carried out with the energy of 30 eV, and all the fragmenta-
tions were observed in the source. Consequently, the ion 
spectra were obtained by scanning from 50 to 500 m/z range. 
Data acquisition software was MassLynx V 4.1 (Waters).
Validation
Validation of the method was performed by the determi-
nation of specificity, accuracy, precision, linearity, limit of 
detection, and limit of quantification [24].
Specificity of the method was assessed by comparing 
chromatograms of pure standards and chromatograms of 
tested solutions after the exposure to UVA radiation, taking 
into account retention time (tR) and resolution factor (Rs) of 
peaks derived from the tested substances and neighboring 
peaks from degradation products.
Accuracy was determined based on sample analysis of 
known concentrations and comparing the results obtained by 
a validated method with true values, followed by calculation 
of the recovery percentage. Determinations were performed 
at three concentration levels: 80%, 100%, and 120%, for each 
of them three repetitions were done.
Precision of the method was determined at three levels 
of drug concentrations in reference solutions: 50%, 100%, 
and 150%. For each concentration level, three repetitions 
were done.
Evaluation of linearity was performed by plotting a 
curve between peak area and concentration of the tested 
substances. For each drug, two series of determinations 
were performed within the concentration ranges described 
in “Standard solutions” section.
Limit of detection and limit of quantification were 
determined from linearity in the concentration ranges: 
AMI  from 0.204 to 1.224 mg cm−3, DOX  from 0.200 
to 1.200 mg cm−3, HAL from 0.214 to 1.284 mg cm−3, 
RIS from 0.214 to 1.284 mg cm−3, VEN from 0.204 to 
1.224 mg cm−3, ZOP from 0.210 to 1.260 mg cm−3, using 
formulas: LOD = 3.3⋅Sy/a, LOQ = 10⋅Sy/a, where: Sy—
estimation error, a—slope of the regression line.
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